BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 12738677)

  • 21. Revised International Prognostic Scoring System (IPSS) predicts survival and leukemic evolution of myelodysplastic syndromes significantly better than IPSS and WHO Prognostic Scoring System: validation by the Gruppo Romano Mielodisplasie Italian Regional Database.
    Voso MT; Fenu S; Latagliata R; Buccisano F; Piciocchi A; Aloe-Spiriti MA; Breccia M; Criscuolo M; Andriani A; Mancini S; Niscola P; Naso V; Nobile C; Piccioni AL; D'Andrea M; D'Addosio A; Leone G; Venditti A
    J Clin Oncol; 2013 Jul; 31(21):2671-7. PubMed ID: 23796988
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Multidimensional assessment of patient condition and mutational analysis in peripheral blood, as tools to improve outcome prediction in myelodysplastic syndromes: A prospective study of the Spanish MDS group.
    Ramos F; Robledo C; Pereira A; Pedro C; Benito R; de Paz R; Del Rey M; Insunza A; Tormo M; Díez-Campelo M; Xicoy B; Salido E; Sánchez-Del-Real J; Arenillas L; Florensa L; Luño E; Del Cañizo C; Sanz GF; María Hernández-Rivas J;
    Am J Hematol; 2017 Sep; 92(9):E534-E541. PubMed ID: 28612357
    [TBL] [Abstract][Full Text] [Related]  

  • 23. International MDS risk analysis workshop (IMRAW)/IPSS reanalyzed: impact of cytopenias on clinical outcomes in myelodysplastic syndromes.
    Kao JM; McMillan A; Greenberg PL
    Am J Hematol; 2008 Oct; 83(10):765-70. PubMed ID: 18645988
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The prognostic value of circulating myeloblasts in patients with myelodysplastic syndromes.
    Duong VH; Padron E; Al Ali NH; Lancet JE; Hall J; Kwok B; Zhang L; Epling-Burnette PK; List AF; Komrokji RS
    Ann Hematol; 2018 Feb; 97(2):247-254. PubMed ID: 29167940
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparing the prognostic value of risk stratifying models for patients with lower-risk myelodysplastic syndromes: Is one model better?
    Zeidan AM; Sekeres MA; Wang XF; Al Ali N; Garcia-Manero G; Steensma DP; Roboz G; Barnard J; Padron E; DeZern A; Maciejewski JP; List AF; Komrokji RS;
    Am J Hematol; 2015 Nov; 90(11):1036-40. PubMed ID: 26284571
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Estimated glomerular filtration rate independently predicts outcome of azacitidine therapy in higher-risk Myelodysplastic syndromes. Results from 536 patients of the Hellenic National Registry of Myelodysplastic and Hypoplastic syndromes.
    Papadopoulos V; Diamantopoulos PT; Papageorgiou SG; Papoutselis M; Vrachiolias G; Pappa V; Galanopoulos AG; Vassilakopoulos TP; Hatzimichael E; Zikos P; Papadaki HA; Bouchla A; Panayiotidis P; Megalakaki A; Papaioannou M; Liapis K; Dryllis G; Tsokanas D; Kourakli A; Symeonidis A; Viniou NA; Kotsianidis I
    Hematol Oncol; 2020 Oct; 38(4):541-553. PubMed ID: 32495951
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [The application of a new prognostic score system for 435 cases of primary myelodysplastic syndrome diagnosed with WHO classification].
    Wang XQ;
    Zhonghua Nei Ke Za Zhi; 2009 Aug; 48(8):633-7. PubMed ID: 19954053
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Enumerating bone marrow blasts from nonerythroid cellularity improves outcome prediction in myelodysplastic syndromes and permits a better definition of the intermediate risk category of the Revised International Prognostic Scoring System (IPSS-R).
    Calvo X; Arenillas L; Luño E; Senent L; Arnan M; Ramos F; Pedro C; Tormo M; Montoro J; Díez-Campelo M; Blanco ML; Arrizabalaga B; Xicoy B; Bonanad S; Jerez A; Nomdedeu M; Ferrer A; Sanz GF; Florensa L
    Am J Hematol; 2017 Jul; 92(7):614-621. PubMed ID: 28370234
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The myelodysplastic syndromes: analysis of prognostic factors and comparison of prognostic systems in 128 Chinese patients from a single institution.
    Zhao WL; Xu L; Wu W; Yan H; Tang W; Hu J; Chen Y; Li JM; Zeng XY; Xiong SM; Shen ZX; Chen Z; Wang ZY; Chen SJ
    Hematol J; 2002; 3(3):137-44. PubMed ID: 12111649
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The prognostic value of monosomal karyotype (MK) in higher-risk patients with myelodysplastic syndromes treated with 5-Azacitidine: A retrospective analysis of the Hellenic (Greek) Myelodysplastic syndromes Study Group.
    Papageorgiou SG; Vasilatou D; Kontos CK; Kotsianidis I; Symeonidis A; Galanopoulos AG; Hatzimichael E; Megalakaki A; Poulakidas E; Diamantopoulos P; Vassilakopoulos TP; Zikos P; Papadaki H; Mparmparousi D; Bouronikou E; Panayiotidis P; Viniou NA; Pappa V
    Am J Hematol; 2018 Jul; 93(7):895-901. PubMed ID: 29659040
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Incorporation of mutations in five genes in the revised International Prognostic Scoring System can improve risk stratification in the patients with myelodysplastic syndrome.
    Hou HA; Tsai CH; Lin CC; Chou WC; Kuo YY; Liu CY; Tseng MH; Peng YL; Liu MC; Liu CW; Liao XW; Lin LI; Yao M; Tang JL; Tien HF
    Blood Cancer J; 2018 Apr; 8(4):39. PubMed ID: 29618722
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Comparison of risk stratification tools in predicting outcomes of patients with higher-risk myelodysplastic syndromes treated with azanucleosides.
    Zeidan AM; Sekeres MA; Garcia-Manero G; Steensma DP; Zell K; Barnard J; Ali NA; Zimmerman C; Roboz G; DeZern A; Nazha A; Jabbour E; Kantarjian H; Gore SD; Maciejewski JP; List A; Komrokji R;
    Leukemia; 2016 Mar; 30(3):649-57. PubMed ID: 26464171
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Age and comorbidities deeply impact on clinical outcome of patients with myelodysplastic syndromes.
    Balleari E; Salvetti C; Del Corso L; Filiberti R; Bacigalupo A; Bellodi A; Beltrami G; Bergamaschi M; Berisso G; Calzamiglia T; Carella AM; Cavalleri M; Da Col A; Favorini S; Forni GL; Goretti R; Miglino M; Mitscheuning L; Molinari E; Racchi O; Scudeletti M; Tassara R; Gobbi M; Lemoli R; Clavio M
    Leuk Res; 2015 Aug; 39(8):846-52. PubMed ID: 26145790
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Mean corpuscular volume predicts prognosis in MDS patients with abnormal karyotypes.
    Wang H; Wang X; Xu X; Lin G
    Ann Hematol; 2010 Jul; 89(7):671-9. PubMed ID: 20179929
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Dynamic assessment of RBC-transfusion dependency improves the prognostic value of the revised-IPSS in MDS patients.
    Hiwase DK; Singhal D; Strupp C; Chhetri R; Kutyna MM; Wee LA; Harrison PB; Nath SV; Wickham N; Hui CH; Gray JX; Bardy P; Ross DM; Lewis ID; Reynolds J; To LB; Germing U
    Am J Hematol; 2017 Jun; 92(6):508-514. PubMed ID: 28247421
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Study on prognostic significances of different cytogenetic risk categories in patients with primary myelodysplastic syndromes].
    Qu SQ; Liu XP; Xu ZF; Zhang Y; Qin TJ; Zhang TJ; Cui R; Hao YS; Xiao ZJ
    Zhonghua Xue Ye Xue Za Zhi; 2011 Dec; 32(12):819-24. PubMed ID: 22339954
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Clinical Outcomes of Decitabine Treatment for Patients With Lower-Risk Myelodysplastic Syndrome on the Basis of the International Prognostic Scoring System.
    Jung KS; Kim YJ; Kim YK; Park SK; Kim HG; Kim SJ; Park J; Choi CW; Do YR; Kim I; Park S; Mun YC; Jeong SH; Kim MK; Yi HG; Chang MH; Kim SY; Lee JH; Jang JH
    Clin Lymphoma Myeloma Leuk; 2019 Oct; 19(10):656-664. PubMed ID: 31375393
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Identification of novel cytogenetic markers with prognostic significance in a series of 968 patients with primary myelodysplastic syndromes.
    Solé F; Luño E; Sanzo C; Espinet B; Sanz GF; Cervera J; Calasanz MJ; Cigudosa JC; Millà F; Ribera JM; Bureo E; Marquez ML; Arranz E; Florensa L
    Haematologica; 2005 Sep; 90(9):1168-78. PubMed ID: 16154839
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A four-parameter index of marrow dysplasia has predictive value for survival in myelodysplastic syndromes.
    Tassin F; Dewé W; Schaaf N; Herens C; Ravoet C; Albert A; Beguin Y; Paulus JM
    Leuk Lymphoma; 2000 Feb; 36(5-6):485-96. PubMed ID: 10784393
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Hypoalbuminemia is an independent prognostic factor for overall survival in myelodysplastic syndromes.
    Komrokji RS; Corrales-Yepez M; Kharfan-Dabaja MA; Al Ali NH; Padron E; Rollison DE; Pinilla-Ibarz J; Zhang L; Epling-Burnette PK; Lancet JE; List AF
    Am J Hematol; 2012 Nov; 87(11):1006-9. PubMed ID: 23090887
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.